Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Glaukos Corporation

Glaukos focuses on developing novel therapies for the treatment of ophthalmic diseases, self-described as pioneering new treatments for chronic eye diseases.

msh id	COM:GLAUKOS
symbol	GKOS
name	Glaukos Corporation
homepage url	https://www.glaukos.com
country	US
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	907
crunchbase url	-
linkedin url	-
founders	-

market cap	6.05B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.15
growth cost of revenue	0.1
growth depreciation and amortization	16.85
growth ebitda	0.22
growth ebitda ratio	0.3
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	0.12
growth gross profit ratio	0

COM:GLAUKOS

Glaukos

Last Close

141.44

21/11 21:00

Market Cap

6.05B

Beta: -

Volume Today

188.50K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	443.41M
cost of revenue	443.41M
depreciation and amortization	37.98M
ebitda	-82.12M
ebitda ratio	-0.26
eps	-2.78
eps diluted	-2.78
operating expenses	367.84M
operating income	-128.7M
operating income ratio	-0.41

accounts receivables	-3.84M
capital expenditure	-20.25M
cash at beginning of period	126.6M
cash at end of period	99.32M
inventory	41.99M
working capital ttm	332.38M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-